Issue: 2016 > November > case report

An impressive response to pazopanib in a patient with metastatic endometrial carcinoma

M.J. van der Steen*, Y.R.P. de Waal*, A. Westermann, B. Tops, W. Leenders, P.B. Ottevanger
AbstractFull textPDF


The incidence of endometrial carcinoma is rising and the patients with distant metastases have a poor prognosis, especially when progression of disease occurs after systemic treatment with hormonal therapy or chemotherapy. Pazopanib, a multi-targeted inhibitor of several oncogenic receptor tyrosine kinases, has been investigated in patients with chemotherapy-resistant endometrial carcinoma or patients for whom chemotherapy is contraindicated. In this report we will describe a spectacular response to pazopanib in a patient with recurrent metastatic endometrial carcinoma.